A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Cisplatin; Doxorubicin; Filgrastim; Paclitaxel; Paclitaxel; Pegfilgrastim
- Indications Endometrial cancer
- Focus Adverse reactions
- 24 Aug 2017 Biomarkers information updated
- 29 Aug 2013 Planned end date changed from 1 Aug 2009 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 07 Mar 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.